Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | SMAD family member 2 | Starlite/ChEMBL | No references |
Homo sapiens | tumor protein p53 | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target/s | Ortholog Group |
---|---|---|---|
Loa Loa (eye worm) | transcription factor SMAD2 | Get druggable targets OG5_131716 | All targets in OG5_131716 |
Echinococcus granulosus | tumor protein p63 | Get druggable targets OG5_140038 | All targets in OG5_140038 |
Loa Loa (eye worm) | MH2 domain-containing protein | Get druggable targets OG5_131716 | All targets in OG5_131716 |
Brugia malayi | MH2 domain containing protein | Get druggable targets OG5_131716 | All targets in OG5_131716 |
Echinococcus multilocularis | tumor protein p63 | Get druggable targets OG5_140038 | All targets in OG5_140038 |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Brugia malayi | MH2 domain containing protein | SMAD family member 2 | 467 aa | 405 aa | 31.6 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Onchocerca volvulus | Transitional endoplasmic reticulum ATPase homolog | 0.1215 | 1 | 0.5 |
Trypanosoma cruzi | Valosin-containing protein, putative | 0.1152 | 0.9416 | 0.5 |
Loa Loa (eye worm) | VCP protein | 0.0502 | 0.3346 | 0.6304 |
Loa Loa (eye worm) | hypothetical protein | 0.0713 | 0.5308 | 1 |
Trichomonas vaginalis | spermatogenesis associated factor, putative | 0.1215 | 1 | 1 |
Echinococcus multilocularis | transitional endoplasmic reticulum atpase | 0.0502 | 0.3346 | 0.117 |
Entamoeba histolytica | transitional endoplasmic reticulum ATPase, putative | 0.1152 | 0.9416 | 0.5 |
Giardia lamblia | AAA family ATPase | 0.0727 | 0.5444 | 0.5 |
Toxoplasma gondii | cell division protein CDC48CY | 0.1215 | 1 | 1 |
Brugia malayi | vesicle-fusing ATPase | 0.0713 | 0.5308 | 1 |
Brugia malayi | transitional endoplasmic reticulum ATPase TER94, putative | 0.0502 | 0.3346 | 0.6304 |
Mycobacterium tuberculosis | Putative conserved ATPase | 0.0727 | 0.5444 | 0.5 |
Trypanosoma brucei | Valosin-containing protein | 0.1152 | 0.9416 | 0.5 |
Plasmodium falciparum | cell division cycle protein 48 homologue, putative | 0.1152 | 0.9416 | 0.5 |
Leishmania major | Transitional endoplasmic reticulum ATPase, putative,valosin-containing protein homolog | 0.1152 | 0.9416 | 0.5 |
Plasmodium vivax | cell division cycle protein 48 homologue, putative | 0.1152 | 0.9416 | 1 |
Mycobacterium ulcerans | ATPase | 0.0727 | 0.5444 | 0.5 |
Loa Loa (eye worm) | vesicle-fusing ATPase | 0.0713 | 0.5308 | 1 |
Toxoplasma gondii | cell division protein CDC48AP | 0.0727 | 0.5444 | 0.0000097958 |
Entamoeba histolytica | cdc48-like protein, putative | 0.1152 | 0.9416 | 0.5 |
Schistosoma mansoni | cell division control protein 48 aaa family protein | 0.1215 | 1 | 1 |
Schistosoma mansoni | cell division control protein 48 aaa family protein | 0.1152 | 0.9416 | 0.9122 |
Echinococcus multilocularis | transitional endoplasmic reticulum atpase | 0.1215 | 1 | 1 |
Brugia malayi | valosin containing protein | 0.0713 | 0.5308 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | = 12.5893 um | PUBCHEM_BIOASSAY: qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 12.5893 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of TGF-b. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588856, AID588860] | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.